Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870044 | 1.00 | HSP90AA1 (0.44) | HSP90AA1MEN1LMNAMAPTKMT2A | |
| SCHEMBL4873492 | 1.00 | HSP90AA1 (0.44) | HSP90AA1MEN1LMNAMAPTKMT2A | |
| SCHEMBL6575270 | 1.00 | HSP90AA1 (0.44) | HSP90AA1MEN1LMNAMAPTKMT2A | |
| SCHEMBL6338945 | 0.92 | MEN1 (0.47) | HSP90AA1MEN1LMNAMAPTKMT2A | |
| SCHEMBL6338942 | 0.92 | MEN1 (0.47) | HSP90AA1MEN1LMNAMAPTKMT2A | |
| SCHEMBL6339170 | 0.92 | MEN1 (0.47) | HSP90AA1MEN1LMNAMAPTKMT2A | |
| SCHEMBL16105229 | 0.85 | CHRNB4 (0.48) | HSP90AA1MEN1LMNAMAPTKMT2A | |
| SCHEMBL2760982 | 0.85 | CHRNB4 (0.48) | HSP90AA1MEN1LMNAMAPTKMT2A | |
| SCHEMBL2760561 | 0.85 | CHRNB4 (0.48) | HSP90AA1MEN1LMNAMAPTKMT2A | |
| SCHEMBL1292952 | 0.85 | CHRNB4 (0.48) | HSP90AA1MEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738710-B2 | Method of treating a patient for pain by administering an anti-ion channel antibody | UCB BIOPHARMA SPRL (BE) | 2017-08-22 | — | — | US | disclosed |
| US-9738710-B2 | Method of treating a patient for pain by administering an anti-ion channel antibody | UCB BIOPHARMA SPRL (BE) | 2017-08-22 | — | — | US | disclosed |
| US-20160222107-A1 | METHODS OF TREATING PAIN USING FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB BIOPHARMA SPRL (BE) | 2016-08-04 | — | — | US | disclosed |
| US-20160222107-A1 | METHODS OF TREATING PAIN USING FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB BIOPHARMA SPRL (BE) | 2016-08-04 | — | — | US | disclosed |
| US-9266953-B2 | Methods of treating pain using function modifying NAv1.7 antibodies | UCB BIOPHARMA SPRL (BE) | 2016-02-23 | — | — | US | disclosed |
| US-9266953-B2 | Methods of treating pain using function modifying NAv1.7 antibodies | UCB BIOPHARMA SPRL (BE) | 2016-02-23 | — | — | US | disclosed |
| US-20150232553-A1 | FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB PHARMA S.A. (BE) | 2015-08-20 | — | — | US | disclosed |
| US-20150232553-A1 | FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB PHARMA S.A. (BE) | 2015-08-20 | — | — | US | disclosed |
| US-20150203571-A1 | ANTIBODIES TO ION CHANNELS | UCB BIOPHARMA SPRL (BE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203571-A1 | ANTIBODIES TO ION CHANNELS | UCB BIOPHARMA SPRL (BE) | 2015-07-23 | — | — | US | disclosed |
| EP-1051394-B1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6429317-B1 | MUSCARINIC RECEPTOR MODULATORS; CENTRAL NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; SCHIZOPHRENIA | ELI LILLY AND COMPANY | 2002-08-06 | — | — | US | disclosed |
| US-6395735-B2 | AN INDANE-LIKE COMPOUNDS WHICH CAN BE USEFUL FOR TREATING PSYCHOSIS AND OTHER CONDITIONS ASSOCIATED WITH MODULATION OF A MUSCARINIC RECEPTOR | ELI LILLY AND COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-6333337-B1 | THE TREATMENT OF CARDIAC ARRHYTHMIAS AND CELL PROLIFERATIVE DISORDERS ARE DESCRIBED. | ICAGEN, INC. | 2001-12-25 | — | — | US | disclosed |
| US-20010012848-A1 | Pharmaceutical compounds | HOLLINSHEAD SEAN PATRICK (US) | 2001-08-09 | — | — | US | disclosed |
| EP-0971885-A4 | PROCESS FOR PREPARING INDANE-LIKE COMPOUNDS | LILLY CO ELI (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1051394-A1 | POTASSIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| EP-0971885-A1 | PROCESS FOR PREPARING INDANE-LIKE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1999037607-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1998031660-A1 | PROCESS FOR PREPARING INDANE-LIKE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012848-A1 | Pharmaceutical compounds | CHRM5, CHRM4, CHRM3 | HSP90AA1 4749/4885MEN1 1772/4885LMNA 4711/4885 |
| US-20150203571-A1 | ANTIBODIES TO ION CHANNELS | SCN1A, KCNAB1, KCNMA1 | HSP90AA1 1729/4885MEN1 2129/4885LMNA 1851/4885 |
| US-20160222107-A1 | METHODS OF TREATING PAIN USING FUNCTION MODIFYING NAv1.7 ANTIBODIES | SCN7A, SCN3A, SCN1A | HSP90AA1 1912/4885MEN1 4300/4885LMNA 1524/4885 |
| US-20150232553-A1 | FUNCTION MODIFYING NAv1.7 ANTIBODIES | SCN7A, SCN1A, SCN5A | HSP90AA1 2425/4885MEN1 4069/4885LMNA 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.